The PPARαγ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat
Joint Authors
Thalén, Pia
Wallenius, Kristina
Löfgren, Lars
Kjellstedt, Ann
Oakes, Nicholas D.
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-14, 14 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-10-27
Country of Publication
Egypt
No. of Pages
14
Main Subjects
Natural & Life Sciences (Multidisciplinary)
Biology
Abstract EN
Metabolic flexibility was assessed in male Zucker rats: lean controls, obese controls, and obese rats treated with the dual peroxisome proliferator activated receptor (PPAR) α/γ agonist, tesaglitazar, 3 μmol/kg/day for 3 weeks.
Whole body glucose disposal rate (Rd) and hepatic glucose output (HGO) were assessed under basal fasting and hyperinsulinemic isoglycemic clamp conditions using [3,3H]glucose.
Indices of tissue specific glucose utilization (Rg′) were measured at basal, physiological, and supraphysiological levels of insulinemia using 2-deoxy-D-[2,6-3H]glucose.
Finally, whole body and tissue specific FFA and glucose utilization and metabolic fate were evaluated under basal and hyperinsulinemic conditions using a combination of [U-13C]glucose, 2-deoxy-D-[U-14C]glucose, [U-14C]palmitate, and [9,10-3H]-(R)-bromopalmitate.
Tesaglitazar improved whole body insulin action by greater suppression of HGO and stimulation of Rd compared to obese controls.
This involved increased insulin stimulation of Rg′ in fat and skeletal muscle as well as increased glycogen synthesis.
Tesaglitazar dramatically improved insulin mediated suppression of plasma FFA level, whole body turnover (Rfa), and muscle, liver, and fat utilization.
At basal insulin levels, tesaglitazar failed to lower HGO or Rfa compared to obese controls.
In conclusion, the results demonstrate that tesaglitazar has a remarkable ability to improve insulin mediated control of glucose and FFA fluxes in obese Zucker rats.
American Psychological Association (APA)
Wallenius, Kristina& Kjellstedt, Ann& Thalén, Pia& Löfgren, Lars& Oakes, Nicholas D.. 2013. The PPARαγ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat. PPAR Research،Vol. 2013, no. 2013, pp.1-14.
https://search.emarefa.net/detail/BIM-461944
Modern Language Association (MLA)
Wallenius, Kristina…[et al.]. The PPARαγ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat. PPAR Research No. 2013 (2013), pp.1-14.
https://search.emarefa.net/detail/BIM-461944
American Medical Association (AMA)
Wallenius, Kristina& Kjellstedt, Ann& Thalén, Pia& Löfgren, Lars& Oakes, Nicholas D.. The PPARαγ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat. PPAR Research. 2013. Vol. 2013, no. 2013, pp.1-14.
https://search.emarefa.net/detail/BIM-461944
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-461944